South Korean drugmaker SK Biopharmaceuticals started the run-in to its $800 million initial public offering by offering more details of its development pipeline, saying it would begin clinical trials …
( read original story …)
The Japan News
South Korean drugmaker SK Biopharmaceuticals started the run-in to its $800 million initial public offering by offering more details of its development pipeline, saying it would begin clinical trials …
( read original story …)